Literature DB >> 11986239

In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia.

Joseph L Wiemels1, Zhijian Xiao, Patricia A Buffler, Ana T Maia, Xiaomei Ma, Brian M Dicks, Martyn T Smith, Luoping Zhang, James Feusner, John Wiencke, Kathy Pritchard-Jones, Helena Kempski, Mel Greaves.   

Abstract

Recent reports have established the prenatal origin of leukemia translocations and resultant fusion genes in some patients, including MLL-AF4 translocations in infants and TEL-AML1 translocations in children. We now report evidence for the prenatal origin of a translocation in childhood acute myeloid leukemia (AML). The t(8;21) AML1-ETO translocations were sequenced at the genomic level in 10 diagnostic leukemia samples from children with available neonatal Guthrie blood spots. Clonotypic genomic AML1-ETO sequences were detected in the Guthrie spots for 5 individuals, providing unambiguous evidence of prenatal origin in these cases. Two of these patients were older than 10 years of age at diagnosis, indicative of a protracted postnatal latency. Three of the patients were assessed for the persistence of genomic fusion sequences in complete clinical remission samples and were found to be positive. These data indicate that t(8;21) in childhood AML can arise in utero, possibly as an initiating event in childhood AML, and may establish a long-lived or stable parental clone that requires additional secondary genetic alterations to cause leukemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986239     DOI: 10.1182/blood.v99.10.3801

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  74 in total

1.  Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Authors:  Heidi J Nick; Hyung-Gyoon Kim; Chia-Wei Chang; Kevin W Harris; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation.

Authors:  P Hirsch; A C Mamez; R Belhocine; S Lapusan; R Tang; L Suner; D Bories; C Marzac; F Fava; O Legrand; M Mohty; L Douay; F Delhommeau
Journal:  Leukemia       Date:  2016-03-01       Impact factor: 11.528

3.  First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation.

Authors:  Christopher J Fraser; Betsy A Hirsch; Vanessa Dayton; Michael H Creer; Joseph P Neglia; John E Wagner; K Scott Baker
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

Review 4.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 5.  A primitive cell origin for B-cell precursor ALL?

Authors:  C V Cox; A Blair
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

Review 6.  Hemangioblasts representing a functional endothelio-hematopoietic entity in ontogeny, postnatal life, and CML neovasculogenesis.

Authors:  Gregor Prindull
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

7.  A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.

Authors:  Shan Lin; Anetta Ptasinska; Xiaoting Chen; Mahesh Shrestha; Salam A Assi; Paulynn S Chin; Maria R Imperato; B J Aronow; Jingsong Zhang; Matthew T Weirauch; Constanze Bonifer; James C Mulloy
Journal:  Blood       Date:  2017-07-14       Impact factor: 22.113

Review 8.  AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Authors:  Megan A Hatlen; Lan Wang; Stephen D Nimer
Journal:  Front Med       Date:  2012-08-09       Impact factor: 4.592

9.  Childhood Leukemia and Primary Prevention.

Authors:  Todd P Whitehead; Catherine Metayer; Joseph L Wiemels; Amanda W Singer; Mark D Miller
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2016-10

Review 10.  Advances in understanding benzene health effects and susceptibility.

Authors:  Martyn T Smith
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.